{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:31:54Z","timestamp":1792089114491,"version":"4.4.0"},"reference-count":35,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2025,3,12]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The relative efficacy of calcineurin inhibitors tacrolimus and cyclosporine in lung transplantation remains unclear. To clarify, we conducted a systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched through EMBASE, MEDLINE and Cochrane CENTRAL until 23 October 2023 for randomised trials comparing tacrolimus with cyclosporine in lung transplant recipients. Data extraction and bias risk assessment were done independently. Analyses included random effects pairwise meta-analysis and trial sequential analysis, with GRADE system for evidence certainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found four eligible trials totalling 662 patients. Tacrolimus significantly reduces the risk of chronic lung allograft dysfunction (RR 0.46, high certainty) and likely decreases acute rejection risk (RR 0.83, moderate certainty), with no clear difference in mortality (RR 1.08, low certainty). It may raise new-onset diabetes mellitus (RR 4.17, low certainty) and renal dysfunction risks (RR 1.27, low certainty).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tacrolimus likely lowers acute rejection and chronic dysfunction risks in lung transplant recipients without improving survival rates. However, it might increase the chances of developing diabetes mellitus and renal dysfunction. These findings guide the choice between tacrolimus and cyclosporine, balancing benefits against potential risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2024-002672","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T01:40:16Z","timestamp":1744335616000},"page":"e002672","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Tacrolimus versus cyclosporine immunosuppression in lung transplantation: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3015-0723","authenticated-orcid":false,"given":"Tyler","family":"Pitre","sequence":"first","affiliation":[{"name":"Division of Respirology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Gurupatham","sequence":"additional","affiliation":[{"name":"Division of Respirology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kairavi","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Binnie","sequence":"additional","affiliation":[{"name":"Division of Respirology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Toronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Martinu","sequence":"additional","affiliation":[{"name":"Division of Respirology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Toronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Juvet","sequence":"additional","affiliation":[{"name":"Division of Respirology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Toronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Zeraatkar","sequence":"additional","affiliation":[{"name":"Health Research Impact and Evidence, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"2026010701503552000_12.1.e002672.1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1164\/ajrccm\/139.2.303","article-title":"Double-lung transplant for advanced chronic obstructive lung disease","volume":"139","author":"Cooper","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"2026010701503552000_12.1.e002672.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198605013141802"},{"key":"2026010701503552000_12.1.e002672.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2019.08.001"},{"key":"2026010701503552000_12.1.e002672.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.07.021"},{"key":"2026010701503552000_12.1.e002672.5","doi-asserted-by":"crossref","unstructured":"Penninga L , Penninga EI , M\u00f8ller CH , et al . Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Cochrane Database Syst Rev 2013;CD008817. doi:10.1002\/14651858.CD008817.pub2","DOI":"10.1002\/14651858.CD008817.pub2"},{"key":"2026010701503552000_12.1.e002672.6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00293-X"},{"key":"2026010701503552000_12.1.e002672.7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026010701503552000_12.1.e002672.8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026010701503552000_12.1.e002672.9","unstructured":"Gordon Guyatt JB . Methods Commentary: Risk of Bias in Randomized Trials 1, 2021. Available: https:\/\/www.evidencepartners.com\/resources\/methodological-resources\/risk-of-bias-commentary"},{"key":"2026010701503552000_12.1.e002672.10","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-217976"},{"key":"2026010701503552000_12.1.e002672.11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-1-0716-1566-9_4","article-title":"Assessing Heterogeneity in Random-Effects Meta-analysis","volume":"2345","author":"Langan","year":"2022","journal-title":"Methods Mol Biol"},{"key":"2026010701503552000_12.1.e002672.12","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90100-P"},{"key":"2026010701503552000_12.1.e002672.13","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-11-916"},{"key":"2026010701503552000_12.1.e002672.14","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bone.2007.07.015","article-title":"The importance of calculating absolute rather than relative fracture risk","volume":"41","author":"Tucker","year":"2007","journal-title":"Bone"},{"key":"2026010701503552000_12.1.e002672.15","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026010701503552000_12.1.e002672.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00242-0"},{"key":"2026010701503552000_12.1.e002672.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2026010701503552000_12.1.e002672.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2019.10.014"},{"key":"2026010701503552000_12.1.e002672.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2022.07.014"},{"key":"2026010701503552000_12.1.e002672.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial Sequential Analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"2026010701503552000_12.1.e002672.21","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.200077"},{"key":"2026010701503552000_12.1.e002672.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2007.07.027"},{"key":"2026010701503552000_12.1.e002672.23","doi-asserted-by":"publisher","DOI":"10.1067\/mtc.2003.71"},{"key":"2026010701503552000_12.1.e002672.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2012.03.008"},{"key":"2026010701503552000_12.1.e002672.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2008.11.016"},{"key":"2026010701503552000_12.1.e002672.26","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00228-024-03750-1","article-title":"Efficacy of tacrolimus versus cyclosporine after lung transplantation: an updated systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials","volume":"80","author":"Suilik","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"2026010701503552000_12.1.e002672.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.06.004"},{"key":"2026010701503552000_12.1.e002672.28","doi-asserted-by":"crossref","DOI":"10.1002\/cesm.12015","article-title":"The impact of blinding on trial results: A systematic review and meta\u2010analysis","volume":"1","author":"Pitre","year":"2023","journal-title":"Cochrane Evidence Synthesis and Methods"},{"key":"2026010701503552000_12.1.e002672.29","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l6802","article-title":"Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study","volume":"368","author":"Moustgaard","year":"2020","journal-title":"BMJ"},{"key":"2026010701503552000_12.1.e002672.30","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1097\/MJT.0000000000000150","article-title":"Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation","volume":"23","author":"Liu","year":"2016","journal-title":"Am J Ther"},{"key":"2026010701503552000_12.1.e002672.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160421","article-title":"Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver Transplant","volume":"11","author":"Muduma","year":"2016","journal-title":"PLoS ONE"},{"key":"2026010701503552000_12.1.e002672.32","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.07.81"},{"key":"2026010701503552000_12.1.e002672.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2019.03.009"},{"key":"2026010701503552000_12.1.e002672.34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.healun.2020.04.012","article-title":"Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system","volume":"39","author":"Levy","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"2026010701503552000_12.1.e002672.35","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.healun.2020.06.024","article-title":"Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations","volume":"39","author":"Cochrane","year":"2020","journal-title":"J Heart Lung Transplant"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2024-002672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:51:21Z","timestamp":1767779481000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2024-002672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,4,10]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bmjresp-2024-002672"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2024-002672","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}